Amylyx Pharmaceuticals (NASDAQ:AMLX) Shares Down 4.6%

Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLXGet Rating) fell 4.6% during mid-day trading on Tuesday . The stock traded as low as $16.98 and last traded at $17.01. 15,130 shares traded hands during mid-day trading, a decline of 99% from the average session volume of 1,523,321 shares. The stock had previously closed at $17.83.

Separately, Citigroup lifted their price objective on shares of Amylyx Pharmaceuticals from $32.00 to $33.00 and gave the company a “buy” rating in a research note on Tuesday, June 14th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $38.50.

The firm’s 50 day simple moving average is $10.58.

Amylyx Pharmaceuticals (NASDAQ:AMLXGet Rating) last announced its earnings results on Thursday, May 12th. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.18). Equities research analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -3.3 EPS for the current year.

Amylyx Pharmaceuticals Company Profile (NASDAQ:AMLX)

Amylyx Pharmaceuticals, Inc, a biopharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada. The company's product candidature includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid for the treatment of ALS and other neurodegenerative diseases.

See Also

Want More Great Investing Ideas?

Receive News & Ratings for Amylyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.